Phase II Trial of Ontak With Metastatic Melanoma
A phase 2 trial of Denileukin diftitox in Melanoma, run by James Graham Brown Cancer Center, completed.
Overview
Phase II Trial of Ontak With Metastatic Melanoma is a phase 2 interventional study registered as NCT00299689 by James Graham Brown Cancer Center, with 69 participants recorded, started 2006-03 and reaching its primary completion in 2010-01. Interventions recorded: Denileukin diftitox. Conditions recorded: Malignant Melanoma.
Linked to the drug Denileukin diftitox because the registry names it among its interventions and Melanoma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialA Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer
Shares Denileukin diftitox and the tag pipeline.
- TrialStudy of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma
Shares Denileukin diftitox, Melanoma and the tag pipeline.
- TrialIntratumoral N17350 in Advanced Solid Tumors
Shares Melanoma and the tag pipeline.
- TrialPhase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors
Shares Melanoma and the tag pipeline.
- TrialSafety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Shares Melanoma and the tag pipeline.
- TrialSafety and Efficacy of OBX-115 in Advanced Solid Tumors
Shares Melanoma and the tag pipeline.
- TrialAn Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
Shares Melanoma and the tag pipeline.
- TrialOH2 Injection in Melanoma
Shares Melanoma and the tag pipeline.